UPDATE: Stifel NIcolaus Cuts Target on OncoGenex Pharmaceuticals to $35

Stifel Nicolaus lowers its price target $4 to $35 on Buy-rated OncoGenex Pharmaceuticals OGXI as the company shift strategy following termination of The SATURN trial. Stifel Nicolaus says, "OncoGenex/Teva announced the termination of the P3 SATURN trial evaluating the durable pain palliation benefits of custirsen (+ docetaxel/cabazitaxel) in second-line CRPC, citing stringent inclusion criteria related to stable baseline pain and analgesic use as bottlenecks to patient enrollment. OncoGenex/Teva now intend to initiate (2H12) a P3 trial evaluating cabazitaxel ± custirsen in second-line CRPC patients (n=630) with overall survival (OS) as the primary endpoint (85% powered at HR=0.75)." OGXI closed at $15.70 a share on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetReiterationIntraday UpdateAnalyst RatingsStifel Nicolaus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!